CRXT News and Press, Clarus Therapeutics Holdings Inc. From 05/16/22

Clarus Therapeutics press release (NASDAQ:CRXT): Q1 GAAP EPS of -$0.61 misses by $0.15. Revenue of $4.01M (+72.1% Y/Y) misses by $0.94M. For further details see: Clarus Therapeutics GAAP EPS of -$0.61 misses by $0.15, revenue of $4.01M misses by $0.94M

First quarter 2022 net revenue increased 72% year-over-year to $4.0 million First quarter 2022 total prescription growth for JATENZO® increased 12% sequentially and increased 75% year-over-year Conference call and webcast today at 5:15 p.m. ET NORTHBROOK, Ill....

Clarus Therapeutics (NASDAQ:CRXT) Q1 consensus EPS estimate is -$0.35 and consensus revenue estimate is $4.95M. CRXT is scheduled to announce Q1 earnings results on Monday, May 16, after market close. For further details see: Clarus Therapeutics Q1 2022 Earnings Preview ...

NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it ...

Initial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women Clarus is seeking Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in the second quarter of 2022 Initiation of Phase 2 clinical trial for CLAR-121 for the treatment ...

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., May 09, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasd...

3 Hot Penny Stocks to Add to Your Watchlist Right Now Recently, we’ve seen major volatility with both penny stocks and blue chips. While volatility can be used as an advantage, for those without a well-thought-out trading strategy, it can be detrimental. If you’re inte...

Penny stocks are generally shares of companies trading for less than $5 per share. While newer traders might consider most to be OTC (over-the-counter) stocks only, there are hundreds of issuers traded on significant exchanges. NYSE and NASDAQ penny stocks have grown in popularity t...

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Upon issuance, this patent will be listed in FDA’s Orange Book, bringing the total number of Orange Boo...

NORTHBROOK, Ill., April 27, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the closing of it...